Intensity Therapeutics’ Stock Doubles After Positive Phase 2 Results for INT230-6
Intensity Therapeutics Inc, a leading late-stage biotechnology company, made a groundbreaking announcement at the 2023 San Antonio Breast Cancer Symposium regarding the Phase 2 INVINCIBLE